Neuroscience

We are committed to researching and developing new, innovative, disease-modifying solutions to address some of the most difficult-to-treat neurologic diseases.

A resilient pursuit to preserve personhood

We are resolute in our commitment to help those living with and affected by the realities of neurologic diseases. We strive to preserve personhood in the face of unrelenting challenges. We stand with patients, their families and healthcare providers to navigate neuroscience’s unchartered frontiers and inevitable setbacks to deliver science that will make a meaningful difference and a remarkable impact on people’s lives.

Almost 10 million

people worldwide currently have Parkinson's disease
_{(source: European Parkinson's Disease Association)}

1 in 4

people over the age of 25 globally will have a stroke in their lifetime
_{(source: World Stroke Organization)}

Migraine is...

one of the leading causes of disability worldwide
_{(source: Steiner, TJ, et al. J Headache Pain. 2018;19(1):17.)}

Depression is...

is a common mental disorder and a leading cause of disability worldwide
_{(source: World Health Organization)}

1 of 4

2 of 4

3 of 4

4 of 4

Teaser1
Teaser2
Teaser3
Teaser4

The path toward transformational therapies

At AbbVie, we invest in neuroscience research that identifies opportunities to help people who live with neurologic disorders. We are advancing research and providing treatments across many neurologic disorders, including Alzheimer’s disease, bipolar disorder, bipolar depression, major depressive disorder, migraine, Parkinson’s disease, post-stroke spasticity, schizophrenia, stroke, and other central nervous system disorders.

We are committed to investing in research that identifies opportunities for real modification, delivering pioneering science, built on inevitable setbacks, that will make a meaningful difference for patients.

Advancing our mission through migraine research and development

Impacting one billion people worldwide, migraine is a neurological disease with recurring attacks that cause pain and other debilitating symptoms. We are committed to advancing science that enables healthcare providers to care for people impacted across the spectrum of migraine. Through education and partnerships with the migraine community, we strive to help those with migraine navigate barriers to care, access effective treatments and reclaim their lives.

Up to 43%

of stroke survivors can develop spasticity, or muscle stiffness and tightness
_{(source: Francisco GE, & McGuire, JR. Poststroke Spasticity Management. Stroke. 2012; 43:3132–3136.)}

Every 3 seconds

a new case of dementia is diagnosed
_{(source: Alzheimer's Disease International)}

1 in 7 people

around the world suffers from migraine
_{(source: Stovner, JL, et al. J Headache Pain. 2022; 23:34)}

Approximately 15% of adults

over the age of 60 experience mental disorders
_{(source: World Health Organization)}